Drugs / Iron (III) Hydroxide Polymaltose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06921343 | Apr 2025 → Dec 2027 expected | celiac disease, disorder of iron metabolism and transport | Kaplan Medical Center | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iron (III) Hydroxide Polymaltose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06921343 ↗ |
| Route | Oral | “Participants randomized to the intervention group will receive oral iron supplementation in addition to a gluten-free diet.” NCT06921343 ↗ |